Utilities of ctDNA for Identifying and Tracking Molecular Residual Disease in Solid Tumors
Time: 12:40 pm
day: Day 1 Track B AM
Details:
- Circulating tumor DNA is an important biomarker in MRD determination, the detection technology is more sophisticated than therapy selection ctDNA assay.
- Considering the prognosis value of using ctDNA to determine MRD status in solid tumor, a number of MRD solutions had been invented and implemented in many clinical studies.
- Burning Rock a tumor-informed personalized MRD assay, brPROPHET, which tracks 50 personalized cancer-specific variants with LoD of 40ppm, and the updated clinical data are presented.
